Floatz logo

Lercanidipine

Hypertension

Università degli Studi dell'InsubriaSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the Hypertension cohort.

Asset / SponsorPhaseRating
VALSARTAN
University of Alabama at Birmingham
Phase 4BBB
Hydrochlorothiazide
University of Kansas Medical Center
Phase 4BBB
AMLODIPINE
Jing Liu
Phase 4BBB
Losartan
Rong Zhang
Phase 4BBB
Trandolapril
University of Florida
Phase 4BBB

View all 50 →

Same molecule, other indications

Lercanidipine is also rated in:

HIV infectious diseaseDormant
B
Indicative ·
62 / 100
View asset →
morbid obesityDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →